mint Lesion™ 1.6

Mint Medical releases mint Lesion™ 1.6 – a major step to facilitate an efficient assessment of tumor therapies mint Lesion™ 1.6 is the third feature release in 2011 – and so far our biggest improvement. Rigorously designed to meet contemporary clinical needs, mint Lesion™ 1.6…

Cooperation with SLK Heilbronn

R&D cooperation with SLK Clinics Heilbronn to optimize the assessment of HCC therapies Targeted therapy methods to treat hepatocellular carcinomas, such as chemoembolization (TACE) or internal radiation therapy (SIRT), are gaining importance in HCC treatment. In this context, criteria like RECIST or WHO provide only…